Pfizer-BioNTech note 95% COVID vaccine efficacy, will apply for EUA

In final results, Pfizer and Germany’s BioNTech announced today that their mRNA-based COVID-19 vaccine has 95% efficacy, even better than the 90% found in its initial analysis, and they will apply for emergency use authorization (EUA) from the US Food and Drug Administration (FDA) within days. The announcement comes as cases in the United States surge to unprecedented levels ahead of the Thanksgiving holiday but brings hope of controlling the virus in 2021. And the final data are comparable to the 94.5% efficacy announced 2 days ago for Moderna’s COVID vaccine.